2023年5月12日

Mindera健康™宣布改变行政领导团队罗恩·罗卡成为首席执行官圣地亚哥,CA - 5月11日,2023 - Mindera健康™,心灵的开发人员。Px™,第一个实现精密医学牛皮癣、行政领导团队已经宣布了一项改变。该公司宣布行业资深罗恩·罗卡将接替乔治Mahaffey担任总裁兼首席执行官。罗卡先生也将作为公司的董事。Mahaffey先生于2020年加入该公司,帮助公司的过渡从研发阶段到Mindera健康的商业发射的第一个测试。“董事会的代表,我想感谢乔治Mindera健康价值的贡献,”乔·库克说,三世,主席Mindera健康和联合创始人兼董事总经理山集团的合作伙伴。“我们都很感激,他执掌以来帮助我们完成,希望他最好的在他未来的事业。”“这是我的荣幸与这样一个才华横溢的专业团队在过去三年中,协助将脑海中。Px精密医学测试市场。祝公司所有,因为他们扩大这一重要的使用和创新技术,“Mahaffey先生说。“我非常兴奋加入Mindera医疗团队。总潜在市场超过20亿美元仅在美国,脑海中。Px has the opportunity to enable huge improvements in patient care while reducing the overall healthcare spend on this disease. In addition to psoriasis, Mindera Health’s proprietary platform also provides access to rich biomarkers that will enable us to develop precision medicine tests for a wide range of diseases,” said Mr. Rocca. Mr. Cook went on to say, “We are very excited to have Ron join Mindera Health as we ramp up our commercial efforts with Mind.Px and advance a number of additional tests in our pipeline. Ron’s demonstrated commitment to help physicians improve patient care while driving commercial adoption and reimbursement aligns well with the mission of Mindera Health.” Mr. Rocca brings over two decades of biotech and diagnostics industry experience, including eleven years of developing and commercializing diagnostic products for autoimmune-related diseases. His prior role was President and CEO of Exagen Inc. (NASDAQ: XGN) which commercialized a suite of testing products enabling healthcare providers to improve care for patients through the differential diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Prior to Exagen, Mr. Rocca served as Vice President, Sales and Marketing, and as General Manager, at Prometheus Laboratories, Inc., a specialty pharmaceutical and diagnostic company focused on diseases in gastroenterology and oncology. He helped grow the company’s sales to $200 million-plus annually before playing an instrumental role in the $1.4 billion acquisition by Nestlé Health Science S.A. in 2011. Prior to Prometheus, Mr. Rocca was the General Manager of Alpharma Inc., a specialty pharmaceutical company. Earlier in his career, Mr. Rocca served in senior sales and marketing management positions for Elan Pharmaceuticals, Inc., a neuroscience-focused biotechnology company. Mr. Rocca received a B.A. in Marketing and Personnel Management from Towson University. Mr. Rocca will assume his new role at Mindera Health immediately. About Mind.Px™ Mind.Px is the flagship test of Mindera Health, designed to prospectively predict a patient’s response to expensive biologic drug classes prior to therapeutic selection and treatment. Using a scalable, minimally invasive dermal biomarker patch that captures over 7,000 biomarkers per sample along with data analytics, Mind.Px materially improves patient outcomes and significantly reduces healthcare system costs of expensive biologic treatments. About Mindera Health™ Mindera Health is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, next-generation sequencing, and machine learning, Mindera Health technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera Health is a CLIA and CAP certified laboratory and has received ISO 13485:2016 certification. Find out more at www.minderahealth.com . About Mountain Group Partners Founded in 2002, Mountain Group Partners is a Nashville-based venture capital firm that invests in early-stage companies in the life sciences and disruptive technology sectors. The firm brings over 100 years of combined operational experience and has invested in more than 60 companies. www.mtngp.com ###